人民财讯12月30日电，12月30日，随着核心设备回旋加速器成功出束，由中广核同位素科技(绵阳)有限 公司投资建设的中能回旋加速器生产医用同位素基地，在四川绵阳正式竣工并启动试生产，构建起覆盖 锗-68、锗镓发生器、铜-64、锆-89、碘-123等多种关键医用同位素的工程化、批量化自主生产能力。 ...

在同位素基地竣工之际，中广核同步正式发布了医用同位素品牌——"和嘉"，寓意"核技术让人类生活 更美好"，传递出对产业高质量发展与民生福祉提升的双重追求。"和嘉"与"IsoNosis"商标同步完成注 册，也将用于旗下各类同位素产品。 12月30日，随着核心设备回旋加速器成功出束，由中广核同位素科技(绵阳)有限公司(简称"中广核同位 素公司")投资建设的中能回旋加速器生产医用同位素基地，在四川绵阳正式竣工并启动试生产，构建起 覆盖锗-68、锗镓发生器、铜-64、锆-89、碘-123等多种关键医用同位素的工程化、批量化自主生产能 力。 医用同位素作为现代核医学的"源头活水"，是恶性肿瘤、心脑血管疾病等重大疾病精准诊断与治疗的核 心物质基础，其稳定供应直接关乎临床诊疗水平与创新药物研发进程。 中广核同位素公司是中广核技（000881）的全资子公司，致力于核药研发、生产、销售和服务的专业化 企业。该公司聚焦临床急需与科研前沿，已形成多元化医用同位素产品矩阵：镓-68作为PET/CT显像(正 电子发射型计算机断层显像)的重要核素，通过中广核同位素公司自主生产的锗镓发生器实现即时衰变 制备，攻克该核素半衰期仅67.71分钟 ...

Core Viewpoint - The company Zhongguang Nuclear Technology announced plans to produce various isotopes, indicating a strategic move towards expanding its product offerings in the isotope market [2] Group 1: Product Development - The isotope company plans to primarily produce germanium-gallium generators, germanium-68, and iodine-123, with the capability for mass production and stable delivery based on customer orders [2] - The company is actively advancing the research and development of copper-64 and zirconium-89 processing technologies [2] - Lutetium-177 is currently only available as an agency sales product, with no plans for independent production at this time [2]

Core Viewpoint - The company emphasizes the importance of domestic substitution strategy for isotopes, particularly focusing on the development and supply of its core product, the germanium-gallium generator, which is currently in a critical phase from technical breakthroughs to large-scale supply [2] Group 1: Domestic Substitution Strategy - The company is prioritizing the domestic substitution strategy for isotopes, indicating a strong commitment to this area [2] - The germanium-gallium generator is undergoing significant technical advancements and is moving towards large-scale supply [2] - The isotope industry is characterized by high technical barriers, strict approval processes, and complex supply chain coordination, requiring multiple verification stages from material preparation to market launch [2] Group 2: Market Development Strategy - The company plans to implement a three-dimensional market strategy consisting of "policy collaboration, customer binding, and ecological co-construction" to enhance market penetration [2] - The company is actively participating in the formulation of industry group standards and collaborating with medical institutions for research and clinical training [2] - The focus on accelerating market development is evident through the company's strategic initiatives [2]

Group 1: Proton Medical Equipment and Isotope Production - Proton medical equipment from the Huaxi project has completed factory production, but installation is pending site readiness, with no acceptance expected this year [2] - The company is focusing on domestic isotope production, particularly the germanium-gallium generator, which is in a critical phase from technical breakthroughs to large-scale supply [2][3] - The company plans to produce isotopes such as germanium-68 and iodine-123, with stable delivery based on customer orders once production starts [3] Group 2: Research and Development Investments - The company has developed a high-power industrial irradiation electron accelerator for disinfection, which offers higher power and efficiency compared to traditional models [4] - New materials like XETFE, suitable for aerospace applications, have been developed, achieving small-scale sales and targeting both domestic and international markets [7] - The company is also advancing in the production of copper-64 and zirconium-89 isotopes, with plans for future industrialization based on market demand [4] Group 3: Financial Performance and Strategic Measures - The company has faced two consecutive years of losses but is implementing measures to reduce costs and increase revenue, including strategic collaborations with major clients [8] - Plans for product transformation and innovation enhancement are underway to align with market demands [8] - The company aims to improve operational efficiency through comprehensive reforms [8]